Self-Identification Program to restore healthier self-identity in adults with depression
Official title: Correct Self-identification Program in the Treatment of Depression: a Randomized Controlled Trial
Run by University Hospital, Montpellier · NCT06183359 · Data updated 2026-11-12
This program tests whether an in-depth third-wave CBT approach focused on correcting self-identification works better than ACT to reduce depressive symptoms and lower relapse risk in adults with a current major depressive episode.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 86 (estimated) |
| Sponsor | University Hospital, Montpellier Academic / other |
| Locations | 1 site (Montpellier) |
| Status | Recruiting |
| Started | August 27, 2024 |
| Main results expected | April 1, 2026 |
| Study ends | February 1, 2028 |
| Registry record updated | September 30, 2025 |
| Trial ID | NCT06183359 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18–70 years old with a current major depressive episode (part of unipolar or bipolar depression), able to give informed consent and attend in-person sessions at CHU Montpellier, are the intended participants.
✕Probably not a fit
Patients with psychotic disorders, active suicidal intent, inability to consent, those not covered by French social security, pregnant or breastfeeding individuals, or those under legal guardianship are unlikely to be eligible or to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a pilot, single-center, randomized two-arm interventional trial comparing a novel Self-Identification Program (SIP; a third-level third-wave CBT intervention) to an active control using Acceptance and Commitment Therapy (ACT). Adults aged 18–70 with a current major depressive episode (unipolar or bipolar) are randomized to receive SIP or ACT, with outcomes measured immediately after treatment and at six months. The primary endpoints are therapeutic response (≥50% symptom reduction from baseline to immediate post-treatment) and relapse rate at six months; secondary measures capture changes in moral pain, rumination, suicidal thoughts, self-concept, functioning, diligence, and psychological skills. The protocol excludes patients with psychotic disorders, active intent to carry out suicide, inability to consent, pregnancy or breastfeeding, and those not covered by French social security.
Why it matters
Potential benefit: If successful, the program could produce larger short-term symptom reductions and lower relapse rates by restoring healthier self-identification and improving related psychological processes.
How similar studies have gone: Related third-wave CBT approaches such as ACT and mindfulness-based therapies have shown benefit for depression, but the specific SIP targeting 'correct self-identification' is a novel, minimally tested intervention.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged 18 to 70 years, presenting a current major depressive episode (according to DSM 571), as part of unipolar or bipolar depressive disorder Exclusion Criteria: * Patients with a psychotic disorder * Patients with active thoughts of suicide with intention to carry out the act (C-SSRS "ideation suicidal" in the last week ≥ 4) * Inability to receive informed information about the study * Exclusion period determined by a previous study * Adult protected by law or patient under guardianship or curatorship * Not be affiliated to a French social security scheme or beneficiary of such a scheme * Not being able to give informed written consent * Pregnant or breastfeeding women * Patients under judicial protection
Where it's running
-
CHU Montpellier
Montpellier, France Recruiting
Study contacts
- Study coordinator: Déborah Ducasse, MD
- Email: d-ducasse@chu-montpellier.fr
- Phone: +33 4 67 33 28 29
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Dupilumab for Major Depressive Disorder
This study tests whether dupilumab can engage immune targets in adults with major depressive disorder to see if it can help with depressive symptoms.
-
Accelerated vs Standard iTBS for Major Depression
This trial tests whether giving more accelerated iTBS sessions is better tolerated and more effective than the standard schedule for adults with major depressive disorder.
-
Psilocybin with Structured Integrated Reframing Therapy for trauma-related MDD and PTSD
This trial tests whether psilocybin therapy, alone or with Structured Integrated Reframing Therapy (SIRT), helps people with trauma-related major depressive disorder who are already on a stable antidepressant.
-
Magnesium Bisglycinate Added to Your Depression Treatment
This study tests whether adding magnesium bisglycinate to your current antidepressant can help reduce depressive symptoms and improve sleep and daily functioning for adults with major depressive disorder.
-
Motif XCS System for treatment-resistant depression
This study tests whether the Motif XCS System is safe and tolerable and might help people with treatment-resistant major depressive disorder.
-
A Phase 3 test of DT120 for major depressive disorder
DT120 is tested against placebo in adults with major depressive disorder to see if it can help reduce depressive symptoms.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.